The technical advances and declining costs of high-throughput genotyping afford investigators fresh opportunities to do increasingly complex analyses of genetic associations with phenotypic and disease characteristics. The leading candidates for such genome-wide association studies (GWAS) are existing largescale cohort and clinical studies that have collected rich sets of phenotype data. To support investigator access to data from these initiatives at the National Institutes of Health (NIH) and elsewhere, the National Center for Biotechnology Information (NCBI) has created a database of Genotypes and Phenotypes (dbGaP) with stable identifiers that make it possible for published studies to discuss or cite the primary data in a specific and uniform way. dbGaP provides unprecedented access to the large-scale genetic and phenotypic datasets required for GWAS designs, including public access to study documents linked to summary data on specific phenotype variables, statistical overviews of the genetic information, position of published associations on the genome, and authorized access to individual-level data (see Box 1 for summary of dbGaP features).
The purposes of this description of dbGaP are threefold: (i) to describe dbGaP's functionality for users and submitters; (ii) to describe dbGaP's design and operational processes for database methodologists to emulate or improve upon; and (iii) to reassure the lay and scientific public that individual-level phenotype and genotype data are securely and responsibly managed. dbGaP accommodates studies of varying design. It contains four basic types of data: (i) study documentation, including study descriptions, protocol documents, and data collection instruments, such as questionnaires; (ii) phenotypic data for each variable assessed, both at an individual level and in summary form; (iii) genetic data, including study subjects' individual genotypes, pedigree information, fine mapping results and resequencing traces; and (iv) statistical results, including association and linkage analyses, when available.
To protect the confidentiality of study subjects, dbGaP accepts only de-identified data and requires investigators to go through an authorization process in order to access individual-level phenotype and genotype datasets. Summary phenotype and genotype data, as well as study documents, are available without restriction.
Phenotypes are described in a structured narrative framework Traditionally, clinical phenotype data have only been shared among a limited group of collaborating researchers-a model that supports documentation of protocols, phenotypes, variables and analysis through paper-based manuals and forms, personal communication or, more recently, electronic access privileges to a project data coordinating center. A centralized resource model, designed specifically for broad data distribution, requires electronically accessible explanations of variables tied closely with the data tables. dbGaP addresses that goal by compiling all available descriptive metadata from participating clinical studies-documentation of protocols, data collection forms, manuals of procedure and the corpus of statistical analyses-putting it in electronic form, and creating explicit links between measured phenotypic variables and related documentation (for example, the measurement for blood pressure at time point 1 is linked to protocol instructions on how and when to take the measurement).
Tiered access for public and authorized users dbGaP is divided into public and authorizedaccess sections for aggregate and individuallevel data, respectively. The public dbGaP website provides a rich set of descriptive statistics for each phenotype variable, allowing users to assess whether the individual-level data may be relevant to their research. Users with required bona fides may download individual-level phenotypic data and genotype
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files, as well as genotype chip intensity files and pedigree information, for use in approved research. Authorization for access to clinical data obligates the investigator and his or her institution to obey data use restrictions dictated by participant informed consent agreements and to comply with requirements detailed in a governing Data Use Certification (DUC) document. Policy details for the GAIN project 1 nicely illustrate the process for GWAS studies in general.
Public access. The public interface at http:// view.ncbi.nlm.nih.gov/dbgap allows users to browse and search study metadata, phenotype variable summary information, documentation, and those association analyses that are in the public domain. It is hoped that these data will stimulate new hypotheses and help investigators identify those datasets that are suitable for their research. Users can quickly navigate to any study and browse or search its components; those interested in specific diseases can browse dbGaP using disease terms linked to the National Library of Medicine (NLM) Medical Subject Headings vocabulary. Users interested in a particular phenotype can use the search interface to query text words against phenotypic variable names and descriptions or against protocols and data collection forms, which contain explicit links to phenotypes.
Authorized access. Authorization for access to individual-level data files is obtained via the dbGaP authorized access portal at http://view. ncbi.nlm.nih.gov/dbgap-controlled. Entry into the system requires that investigators have either an NIH eRA Commons Account (extramural researchers) or an NIH login (intramural researchers) and that they be classified as principal investigators (PIs). Non-PIs cannot independently apply for access to individual-level data; however, they can be approved for local access to downloaded data files within the PI's lab if they are listed as collaborating investigators on a PI's application. Although the NCBI provides the interface for requests and downloads, data authorization decisions are made by the NIH institute that sponsors each study in dbGaP. The dbGaP authorized access portal authenticates users requesting access against the NIH eRA Commons system, provides the necessary forms and forwards completed requests to the appropriate NIH Data Access Committee (DAC) for review. DAC review criteria vary by program; however, all reviews seek to ensure that the stated research purposes are compatible with participant consent and that the PI and his or her institution will abide by the study's data use certification and terms of use. Once access has been granted, researchers can log into the system and download the deidentified individual-level data files for which they have approval.
Publication
For many studies in dbGaP, the investigators who contributed the data will retain the exclusive right to publish analyses of the dataset for a defined period of time after its release in dbGaP, typically 9 or 12 months. The date that the exclusive publication rights expire is called the embargo release date in dbGaP. During this period of exclusivity, other investigators may be granted access to download and analyze the data, but they are expected not to seek publication of their analyses or conclusions until the embargo release date. Embargo release dates are provided in several places: (i) the public dbGaP home page's list of studies (ii) the pub- Accession numbers in dbGaP are created separately for a study and its subordinate objects -phenotype variables, phenotype trait tables, documents and genotype datasets -prefixed phs, phv, pht, phd and phg, respectively. Accession numbers have suffixes "v" for data version, "p" for participant set version and "c" for consent group version. Phenotype and genotype data are distributed as both public summary records and individual-level data that require authorization to use. Associations between genotypes and phenotype traits of interest are not subordinate objects of a study, as an analysis may include data components from several studies simultaneously.
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lic dbGaP summary pages for each study and (iii) file download manifests that accompany each authorized-use data download.
Data security
High-density genomic data, even when deidentified, remain unique to the individual and could potentially be linked to a specific person if used in conjunction with other databaseshence the need for security around the storage, distribution and use of these data. Lowrance and Collins 2 provide a detailed exposition of the identifiability issues surrounding these data and conclude that protecting the privacy and confidentiality of participant research data is a shared responsibility between submitters, repositories and authorized users. These data must be managed with care to maintain public trust.
In accordance with these principles, the NCBI only releases de-identified data as encrypted files to authorized users. It is the responsibility of each PI to establish a secured computing facility for local use of the data. Best practices for configuring a secure network are described at http://www.ncbi.nlm.nih.gov/ projects/gap/pdf/dbgap_2b_security_proce-dures.pdf.
The goal of this process is to ensure that data provided by the NIH are kept sufficiently secure and are not released, through either malicious or inadvertent means, to any person not permitted to access them. To accommodate these requirements, systems housing authorizedaccess data must not be directly accessible from the Internet, and the data must not be posted on any web or ftp server. Data placed on shared systems must be secured and access must be limited to those involved in the research for which the data has been requested. If data are stored on laptops or removable devices, those devices must be encrypted.
Authorized data include all instances of individual-level data. When specific studies are subject to an embargo release date, authorized data also include certain summary data, such as the results of precomputed association or genetic linkage tests. These summary components are distributed through the authorized access mechanism until the embargo release date has passed. Afterwards, these data will be freely available through the public dbGaP FTP site.
dbGaP accessioned objects
The accessioned objects of dbGaP include studies, phenotype trait tables, phenotype variables, documents, genotypes and analyses (Fig. 1) .
A study is the largest unit of submitted content organized and accessioned by dbGaP. The organization of studies in the database can be hierarchical: a top-level study may contain sub-studies reflecting an intuitive or historical NATURE GENETICS | VOLUME 39 | NUMBER 10 | OCTOBER 2007 1 1 8 3 
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grouping of the data. dbGaP generally includes a high-level description of the study, a timeline or history, a bibliography of related published articles, and attribution for study investigators. In addition, studies can be browsed by tagged disease terms. The database is designed to accommodate studies with any number of sub-studies, phenotypic variables, documents, genotype batches and analyses. Each study is assigned a unique, stable and versioned identifier (ID) prefixed by "phs," indicating a phenotype study. The ID is suffixed by both a version number (.v#) that increases when changes occur to data columns (phenotype values) and a participant set number (.p#) that increases when the number of individuals in a set changes as a result of alterations in informed consent status. An example of a study accession in dbGaP is phs000001.v1.p1, where v1 indicates the data version and p1 indicates the participant set version. To comply with current subject consents, authorized downloads of individual-level data will be limited to only the most recent participant set, both for current and previous versions. For each phenotype variable, several descriptive statistics are calculated: mean, median, standard deviation, minimum value and maximum value. Categorical variables are reported with the frequency of each response. The number of missing (null) values for each phenotype measurement is listed along with the overall number of individuals in the dataset (n). Individuals in datasets are separately classified by sex, case-control status and consent category. When appropriate, variable distributions are presented separately for cases and controls, with accompanying statistics for deviation of cases from controls. Phenotypic variables are assigned "phv" (phenotype variable) identifiers along with increasing numeric suffixes for new versions and participant sets, similar to studies. Document parts, such as clinical protocols, play an integral role in defining phenotypic variables in dbGaP and aid a user's understanding of a variable. Thus, changes to documents or other metadata that significantly alter the meaning of a variable also result in a new variable version. Changes in participant sets will alter the statistical summary of values and prompt the regeneration of all versions of data files to reflect the new consent structure. Although individual-level data from obsolete participant sets will not be available for authorized download, prior summaries will be maintained on the public website.
Phenotype variables

Data submission
Before a study is submitted to dbGaP, submitting institutions must certify that (i) all applicable laws and regulations have been followed; (ii) the data submitted to dbGaP is de-identified consistent with the Health Insurance Portability and Accountability Act (HIPAA) of 1996 Privacy Rule and Title 45 Part 46 of the Code of Federal Regulations; and (iii) the submission and subsequent sharing of the data is consistent with the informed consent of participants from whom the data was obtained. If the study is not sponsored by the NIH, the investigators must reach an agreement with an NIH Institute to have a Data Access Committee manage data access requests for the study data.
After these assurances are met, dbGaP staff will work with the primary investigator to correctly reflect the study's logical organization, documentation, phenotype datasets and individual informed consent categories. Although the NCBI works with the primary investigator to identify and remove any detectable errors in the 
BOX 1 Summary of dbGaP features and access structure
Key features of dbGaP • The database of Genotypes and Phenotypes (dbGaP) was developed to archive and distribute the results of studies that have investigated the association between genotype and phenotype.
• Content for each submitted study is comprehensive, including study documents (protocols, questionnaires and so on), phenotype measures, genetic data derived from genotyping arrays or sequencing experiments, and details of statistical associations between phenotypes and genotypes.
• Phenotype measurements are linked to the related study documentation. Measurement data are accepted in diverse formats and are converted into a common distribution format without modification or standardization by the National Center for Biotechnology Information (NCBI).
• All content receives stable, unique public accession identifiers (IDs), allowing specific data or studies to be cited in publications or pointed to from within other bioinformatics resources.
• Data are distributed in a uniform download format across studies.
• All individual-level data are de-identified by the submitter; individuals are represented by coded IDs, and the National Institutes of Health (NIH) does not hold or have access to the keys. Data access structure • Study protocols and summary phenotype and genotype data are available to the public without restrictions on use.
• Access to individual-level data requires preauthorization from sponsoring NIH programs. Use of the data are limited to approved research activities, and must follow the basic principles set forth in the NIH policy for genome-wide association studies (GWAS).
• Association data may be limited to the authorized-access portion of dbGaP during an initial embargo period designed to give submitters exclusivity on publishing their data. After expiration of the embargo period, the association data will move to the public portion of the database.
• Authorized-access data should be used in a secured computing environment and in accord with the applicable terms of use for the specific dataset(s): for example, restrictions on use defined by participant informed consent agreements, prohibitions on redistributing the data, and compliance with restrictions on the public dissemination of results during embargo periods.
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data, the NCBI does not warrant the accuracy, quality or fitness of dbGaP data for any particular purpose.
Study documents
The dbGaP document system formats, accessions, indexes and displays all submitted study documentation in such a way that (i) links are created between the variable values in the database and their references in the documents; (ii) document representation can be rendered in a web browser for easy navigation between variable summary report pages and their referencing documents; and (iii) a framework is established that will support future generation of web-based forms and questionnaires that capture variable data directly into dbGaP. To achieve these goals, documents are encoded using XML (eXtensible Markup Language), which allows semantic annotation of documents and is used to link phenotypes with the parts of documents that describe how they were measured. This type of encoding lends itself naturally to creating multiple output streams (such as output in HTML and PDF formats), and allows for later reuse and repurposing of the documents 3, 4 .
Document models and markup. The NCBI created and maintains the NLM Archiving and Interchange XML TagSet and the NLM Archiving and Interchange DTD, a schema defined using elements from the TagSet to mark up journal articles in PubMed Central, the NLM's electronic archive of full-text life sciences journal literature. Extensions to the NLM DTD that support study documents, such as protocols and questionnaires, are available (see Supplementary Note online). Study documents receive a unique stable identifier, along with the "phd" prefix that indicates a phenotype document, and a version suffix (for example, phd000001.1); this full identifier should be cited in publications.
Genotypes dbGaP archives genotype data from study samples and distributes these data, providing investigators with direct access to raw data. Availability of this raw data allows subsequent analyses using new techniques that may evolve and new best practices. Unfiltered genotype datasets include such raw data as microarray probe intensity data, normalized allele-specific signal intensities and pregenerated genotype cluster plots, as well as vendor-supplied genotype calls. As investigators apply new techniques, such as improved genotype-calling algorithms, these results can be incorporated into dbGaP as additional versions of the genotype data. Before genotype data are released, several checks are applied to confirm sample tracking and family relationships, including tests for mendelian inheritance and for gender agreement with the manifest file, comparison with previous genotypes, and checks for unexpected duplicate samples. Samples flagged as presenting genotypes from the wrong individual are excluded from the data release. Genotypes are provided in a compact matrix format, and may be available in a more expansive format with one genotype per row. All genotypes are reported in genomic orientation. Sets of genotypes on a particular platform across all individuals are assigned a unique and stable "phg" identifier along with a version and participant set.
Data cleaning and quality control
The thresholds used during the data-cleaning process, and the resulting selection of which individuals and markers to use as input to downstream analysis, profoundly affect the results as well as the reproducibility of analyses. Thus, dbGaP works collaboratively with data submitters and the study advisory committee to create a documented process of data cleaning as well as the filtered dataset used to generate the analyses (discussed in the next section). Sample quality control metrics include genotype call rate, sex prediction, average heterozygosity, likelihood of observed genotypes and mendelian error rate. Marker-specific quality control metrics include mendelian error rate per marker, Hardy-Weinberg equilibrium test P value, call rate, duplicate concordance rate, rate of concordance with known genotypes, minor allele frequency and vendor-supplied genotype quality score. Summary results and selected thresholds are provided publicly when available; detailed and embargoed results are components of the authorized-access release.
The process of selecting quality control thresholds and analysis may be iterative. A shared pattern of quality control metrics among highly significant markers revealed by a preliminary association test may signal a common false-positive error mode. dbGaP provides several metrics to detect statistical inflation in the data, such as quantile-quantile plots of Cochran-Armitage test statistics 5 and genomic control lambda values 6 , for consideration by the study investigators and advisory committee as they optimize data-cleaning thresholds. These conclusions are documented as part of the genotype release, and the resulting dataset is provided as the filtered release set.
In addition to the filtered set of high-quality genotype data, all remaining genotype data that fail Hardy-Weinberg or mendelian inheritance checks will be available for investigator use, with flags for the set of quality filters they failed to pass. These data that failed quality checks are provided because they may occasionally contain information of value, but they should be used with the requisite cautions.
C O M M E N TA R Y
ining the association between phenotype and genotype. At the time of writing, dbGaP has 12 public studies at various stages of completion. Data for several other genome-wide association studies are being processed and will be made public in the next several months. Table 1 lists the studies that are expected to be available in dbGaP through 2007 and into 2008; together they will include data from well over 100,000 individuals measured for thousands of distinct phenotypic variables. In addition to genomewide association and linkage studies, dbGaP will store medical sequencing studies, finemapping studies, and literature and database reviews of disease-causing mutations. There are obvious links between these types of studies, some of which will be follow-up analyses of other studies in dbGaP.
Publication references to dbGaP studies dbGaP provides a critical contribution to the scientific community by establishing a central repository for uniform representation of clinical phenotype, genotype and analysis data that can be accessed and browsed through a common interface. Published analyses of data from dbGaP should explicitly reference unique and stable accession numbers in method descriptions and acknowledge each study used as directed by the Data Use Certification.
Publications that reference a dbGaP analysis dataset should reference the unique and stable "pha" identifier assigned to that analysis. Embargoed data have an Embargo Release Date clearly indicated for each set of downloaded data. Studies subject to embargo release dates are clearly indicated on the public dbGaP search page and on each study's respective description page.
Future directions
The dbGaP database schema is designed to generally store phenotype data that can be associated with other relevant data types, including genotypes, sequence-derived genotypes and haplotypes, and gene expression, proteomic, metabolomic and epigenetic data. Although current GWAS activity is focused on high-density microarray genotype data, new programs such as the National Human Genome Research Institute (NHGRI) medical sequencing initiative will couple phenotype data with data from new technologies such as short-read sequencing. Additionally, the database is not restricted to clinical data or even to human data. In the future, the underlying architecture of dbGaP could be used as a repository for data from model organisms of human disease and for data on other nonclinical traits, such as agricultural phenotypes. 
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